Plasma Soluble Interleukin-2 Receptors in Patients with Myelodysplastic Syndromes

References

• Kono T., Minami Y., Taniguchi T. The interleukin‐2 receptor complex and signal transduction: role of the beta‐chain. Seminars in Immunology 1993; 5: 299–307
   PubMedGoogle Scholar
• Nakamura M., Asao H., Takeshita T., Sugamura K. Interleukin‐2 receptor heterotrimer complex and intracellular signaling. Seminars in Immunology. 1993; 5: 309–317
   PubMedGoogle Scholar
• Mingari M. C., Gerosa F., Carra G., Accolla R. S., Moretta A., Zubler R. H., Waldmann T. A., Moretta L. Human interleukin‐2 promotes proliferation of activated B‐cells via surface receptors similar to those of activated T‐cells. Nature 1984; 312: 641–643
   PubMed Web of Science ®Google Scholar
• Morgan D. A., Ruscetti F. W., Gallo R. Selective in vitro growth of T‐lymphocytes from normal human bone marrows. Science 1976; 193: 1007–1008
   PubMed Web of Science ®Google Scholar
• Siegel J. P., Sharon M., Smith P. L., Leonard W. J. The IL‐2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 1987; 238: 75–78
   PubMed Web of Science ®Google Scholar
• Ambrosetti A., Semenzato G., Prior M., Chilosi M., Vinante F., Vincenzi C., Zanotti R., Trentin L., Portuese A., Menestrina F., Perona G., Agostini C., Todeschini G., Pizzolo G. Serum levels of soluble interleukin‐2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. British Journal of Haematology. 1989; 73: 181–186
   PubMed Web of Science ®Google Scholar
• Motoi T., Uchiyama T., Hori T., Itoh K., Uchino H., Ueda R. Elevated serum‐soluble interleukin‐2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood 1989; 74: 1052–1057
   PubMed Web of Science ®Google Scholar
• Waldmann T. A., Greene W. C., Sarin P. S., Saxinger C., Blayney D. W., Blattner W. A., Goldman C. K., Bongiovanni K., Sharrow S., Depper J. M., Leonard W., Uchiyama T., Gallo R. C. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T‐cell leukemia with human T‐cell leukemia/ lymphoma virus negative Sezary leukemia, and their distinction using anti‐Tac. Monoclonal antibody identifying the human receptor for T‐cell growth factor. Journal of Clinical Investigation. 1984; 73: 1711–1718
   PubMed Web of Science ®Google Scholar
• Korsmeyer S. J., Greene W. C., Cossman J., Hsu S. M., Jensen J. P., Neckers L. M., Marshall S. L., Bakhshi A., Depper J. M., Leonard W. J., Jaffe E. S., Waldmann T. A. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proceedings of the National Academy of Sciences of the United States of America. 1983; 80: 4522–4526
   PubMed Web of Science ®Google Scholar
• Nakase K., Kita K., Otsuji A., Anazawa H., Hoshino K., Sekine T., Shirakawa S., Tanaka I., Nasu K., Tsutani H., Dohy H., Tsudo M. Diagnostic and clinical importance of interleukin‐2 receptor alpha chain expression on non‐T‐cell acute leukaemia cells. British Journal of Haematology. 1992; 80: 317–326
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. Journal of Immunology 1985; 135: 3172–3177
   PubMed Web of Science ®Google Scholar
• Loughnan M. S., Sanderson C. J., Nossal G. J. Soluble interleukin 2 receptors are released from the cell surface of normal murine B lymphocytes stimulated with interleukin 5. Proceedings of the National Academy of Sciences of the United States of America 1988; 85: 3115–3119
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Galli F., Greene W. C., Nelson D. L., Jay G. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine 1990; 2: 330–336
   PubMedGoogle Scholar
• Rubin L. A., Jay G., Nelson D. L. The released interleukin 2 receptor binds interleukin 2 efficiently. Journal of Immunology 1986; 137: 3841–3844
   PubMed Web of Science ®Google Scholar
• Symons J. A., Wood N. C., Di G. F., Duff G. W. Soluble IL‐2 receptor in rheumatoid arthritis. Correlation with disease activity, IL‐1 and IL‐2 inhibition. Journal of Immunology 1988; 141: 2612–2618
   PubMed Web of Science ®Google Scholar
• Yamaguchi S., Onji M., Ohta Y. Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases. Hepato Gastroenterology 1988; 35: 245–248
   PubMed Web of Science ®Google Scholar
• Kloster B. E., John P. A., Miller L. E., Rubin L. A., Nelson D. L., Blair D. C., Tomar R. H. Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clinical Immunology & Immuno‐pathology 1987; 45: 440–446
   PubMedGoogle Scholar
• Griffin D. E., Ward B. J., Jauregui E., Johnson R. T., Vaisberg A. Immune activation in measles. New England Journal of Medicine 1989; 320: 1667–1672
   PubMed Web of Science ®Google Scholar
• Tung K. S., Umland E., Matzner P., Nelson K., Schauf V., Rubin L., Wagner D., Scollard D., Vithayasai P., Vithayasai V., Worobec S., Smith T., Suriyanond V. Soluble serum interleukin 2 receptor levels in leprosy patients. Clinical & Experimental Immunology 1987; 69: 10–15
   PubMed Web of Science ®Google Scholar
• Keystone E. C., Snow K. M., Bombardier C., Chang C. H., Nelson D. L., Rubin L. A. Elevated soluble interleukin‐2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis & Rheumatism 1988; 31: 844–849
   PubMed Web of Science ®Google Scholar
• Wolf R. E., Brelsford W. G. Soluble interleukin‐2 receptors in systemic lupus erythematosus. Arthritis & Rheumatism 1988; 31: 729–735
   PubMed Web of Science ®Google Scholar
• Lang B. A., Silverman E. D., Laxer R. M., Rose V., Nelson D. L., Rubin L. A. Serum‐soluble interleukin‐2 receptor levels in Kawasaki disease. Journal of Pediatrics 1990; 116: 592–596
   PubMed Web of Science ®Google Scholar
• Gallo P., Piccinno M. G., Pagni S., Argentiero V., Giometto B., Bozza F., Tavolato B. Immune activation in multiple sclerosis: study of IL‐2, sIL‐2R, and gamma‐IFN levels in serum and cerebrospinal fluid. Journal of the Neurological Sciences 1989; 92: 9–15
   PubMed Web of Science ®Google Scholar
• Lawrence E. C., Holland V. A., Young J. B., Windsor N. T., Brousseau K. P., Noon G. P., Whisennand H. H., Debakey M. E., Nelson D. L. Dynamic changes in soluble interleukin‐2 receptor levels after lung or heart‐lung transplantation. American Review of Respiratory Disease 1989; 140: 789–796
   PubMed Web of Science ®Google Scholar
• Marcon L., Rubin L. A., Kurman C. C., Fritz M. E., Longo D. L., Uchiyama T., Edwards B. K., Nelson D. L. Elevated serum levels of soluble Tac peptide in adult T‐cell leukemia: correlation with clinical status during chemotherapy. Annals of Internal Medicine 1988; 109: 274–279
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Cetto G., Ambrosetti A., Fiore D. L., Perona G., Berton G., Lestani M., Scarpa A., Agostini C., Trentin L., Zambello R., Masciarelli M., Dazzi F., Viante F., Caligaris‐Cappio F., Pizzolo G. Soluble interleukin‐2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha‐interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987; 70: 1530–1535
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Vinante F., Menestrina F., Piazzola E., Focchiatti V., Sabbioni R., Zanotti R., Pizzolo G. Increased levels of soluble interleukin‐2 receptor in non‐Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotypic features. American Journal of Clinical Pathology 1989; 92: 186–191
   PubMed Web of Science ®Google Scholar
• Nelson D. L., Wagner D. K., Marcon L., . An analysis of soluble IL‐2 receptor in human neoplastic disorders. Biotechnology in Clinical Medicine, A. Albertini, C. Lentant, R. Poeletti, et al. Raven Press, New York 1987; 277–286
   Google Scholar
• Takamatsu T., Yasuda N., Ohno T., Kanoh T., Uchino H., Fujisawa A. Soluble interleukin‐2 receptors in the serum of patients with chronic renal failure. Tohoku Journal of Experimental Medicine 1988; 155: 343–347
   PubMed Web of Science ®Google Scholar
• Zwierzina H., Herold M., Schollenberger S., Geissler D., Schmalzl F. Detection of soluble IL‐2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM‐CSF. British Journal of Haematology 1991; 79: 438–443
   PubMed Web of Science ®Google Scholar
• Yokose N., Ogata K., Ito T., An E., Tamura H., Dan K., Hamaguchi H., Sakamaki H., Onozawa Y., Nomura T. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T‐cells in myelodysplastic syndromes. Leukemia Research 1994; 18: 777–782
   PubMed Web of Science ®Google Scholar
• Ogata K., Yokose N., An E., Kamikubo K., Tamura H., Dan K., Sakamaki H., Onozawa Y., Hamaguchi H., Nomura T. Plasma soluble interleukin‐2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. British Journal of Haematology 1996; 93: 45–52
   PubMed Web of Science ®Google Scholar
• Janssen J. W., Buschle M., Layton M., Drexler H. G., Lyons J., van den Berghe H., Heimpel H., Kubanek B., Kleihauer E., Mufti G. J., Bartram C. R. Clonal analysis of myelodysplastic syndromes: evidence of multi‐potent stem cell origin. Blood 1989; 73: 248–254
   PubMed Web of Science ®Google Scholar
• Tefferi A., Thibodeau S. N., Solberg L. J. Clonal studies in the myelodysplastic syndrome using X‐linked restriction fragment length polymorphisms. Blood 1990; 75: 1770–1773
   PubMed Web of Science ®Google Scholar
• Hamaguchi H., Takano N., Saito K., Enokihara H., Furusawa S., Shishido H. Interaction of monocytes and T cells in the regulation of normal human mega‐karyocytopoiesis in vitro: role of IL‐1 and IL‐2. British Journal of Haematology 1990; 76: 12–20
   PubMed Web of Science ®Google Scholar
• Hogan P. G., Basten A. What are killer cells and what do they do?. Blood Reviews 1988; 2: 50–58
   PubMed Web of Science ®Google Scholar
• Herberman R. B. Tumor immunology. Journal of the American Medical Association 1992; 268: 2935–2939
   PubMed Web of Science ®Google Scholar
• Haller O., Hansson M., Kiessling R., Wigzell H. Role of non‐conventional natural killer cells in resistance against syngeneic tumour cells in vivo. Nature 1977; 270: 609–611
   PubMed Web of Science ®Google Scholar
• Garcia P. P., Koster F. T., Kelley R. O., McDowell T. D., Bankhurst A. D. Antibacterial activity of human natural killer cells. Journal of Experimental Medicine 1989; 169: 99–113
   PubMed Web of Science ®Google Scholar
• Pistoia V., Ghio R., Nocera A., Leprini A., Perata A., Ferrarini M. Large granular lymphocytes have a promoting activity on human peripheral blood erythroid burst‐forming units. Blood 1985; 65: 464–472
   PubMed Web of Science ®Google Scholar
• Robertson M. J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421–2438
   PubMed Web of Science ®Google Scholar
• Ohmori M., Ueda Y., Masutani H., Hirama T., Anzai N., Yoshida Y., Okuma M. Myelodysplastic syndrome (MDS)‐associated inhibitory activity on haematopoietic progenitor cells: contribution of monocyte‐derived lipid containing macrophages (MDLM). British Journal of Haematology 1992; 81: 67–72
   PubMed Web of Science ®Google Scholar
• Ogata K., Fujii H., Yokose N., An E., Tamura H., Kamikubo K., Dan K., Hamaguchi H., Sakamaki H., Onozawa Y., Nomura T. Defective natural killer (NK) cell‐mediated cytotoxicity does not imply clonal involvement of NK cells in myelodysplastic syndromes. British Journal of Haematology 1994; 87: 396–398
   PubMed Web of Science ®Google Scholar